1 / 21

Promoting Adherence and Retention in ARV-based Prevention

Promoting Adherence and Retention in ARV-based Prevention. Dr. Seema Sahay, Ph.D Division of Social and Behavioral Research National AIDS Research Institute Indian Council of Medical Research, Pune (India). Overview. Defining and measuring adherence Issues around adherence

desiree-burgess
Télécharger la présentation

Promoting Adherence and Retention in ARV-based Prevention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Promoting Adherence and Retention in ARV-based Prevention Dr. Seema Sahay, Ph.D Division of Social and Behavioral Research National AIDS Research Institute Indian Council of Medical Research, Pune (India)

  2. Overview • Defining and measuring adherence • Issues around adherence • The adherence framework • Individual, Product, Provider and Community • Lessons learnt from treatment adherence • Adherence in HIV prevention trials • Known drivers of adherence • Meeting the adherence challenges • Addressing retention • The CLUB message

  3. What is adherence? • WHO defines adherence: • ‘The extent to which a person’s behavior – taking medication, following a diet, and/or executing lifestyle changes – corresponds with agreed recommendations from a health care provider’ . • Multidimensional: Interplay of participant behavior, adverse effect profiles, patient fatigue, and integration of therapy into the routine of daily living. Adherence in HIV prevention – To take / use the drug as prescribed in order to achieve optimal drug levels at the time of exposure to virus.

  4. Measuring adherence • Self-report use / recall • Direct measures • Smart applicators • Wise Pill/Bags • Unannounced product count • Biomarkers – drug levels • Triangulation of measures – combination of different measures

  5. Issues around ARV based prevention • How do we ensure that the drug/ product is available at the time of potential HIV exposure (when it relies on self-directed use)? • Who would be the potential users? Key populations? • In real life scenarios, how should PrEP products be positioned? • How do we promote adherence to drugs/ interventions in non-therapeutic situations?

  6. Adherence Framework Environmental Economic

  7. Individual • Motivations for using the product – perception of self risk • Time when product use might be most desirable: Example: desire to conceive • Convenient to incorporate into lifestyle • Is the product empowering? • Relationship dynamics • Attitudes and beliefs towards the product

  8. Product • Delivery vehicle • Oral – tablets • Vaginal - gels, rings, films • Regimen • Dosing and timing • Daily vs coitally • Product characteristics • Sticky, drippy, dry, smell, color, taste,too large to swallow • Potential side effects

  9. Provider • Is the provider equipped with necessary information? – Training / Skills • Is the provider community literate? • Are appropriate educational aids available? • Support of strengthened health care system • How would linkages between ARV delivery and prevention programs be established?

  10. Community • Disclosure to partner and families • For TasP: partner’s support would be useful • Stigma / discrimination • Example: ARVs and TB drugs • Community understanding of product • Buy-in at all levels of government / DoH is critical • Country, province, states, district, municipality

  11. Lessons learnt from treatment adherence • Buddy system – providing support • Treatment clubs – delivery of drugs to patient’s homes and discussing experiences • Prescription and drug dispensing for longer period • Partner support • Peer involvement and community education • Empowered health educators, nurses or community health workers • Cell phone reminders • Unannounced pill counts

  12. Effectiveness in PrEP trials is strongly correlated with adherence levels Pearson correlation = 0.86, p=0.003 Source: Prof Salim Abdool Karim, CAPRISA

  13. Lessons learnt from ARV prevention trials • * Respect the individual * • Identify barriers to adherence and help the individual come up with solutions • Product must suit the individual's lifestyle, i.e. if sex is infrequent then a daily dose may not suit the need • Encourage honesty – providers should not be judgemental

  14. Known drivers of adherence

  15. Risk perception: a key indicator of adherence • Short message surveys for PrEP[K. Curran et al, 2013] • Missed doses were correlated with sexual abstinence • Unprotected sex was not associated with decreased PrEP adherence • Low perception of HIV risk could explain low PrEP adherence [Van Damme et al, 2012] • Self-perception of risk might increase PrEP use [Grant et al, 2010] Perceived self risk would be an indicator of adherence

  16. Promoting adherence: challenges ahead • Individual: • Self-perceived HIV risk: generally healthy! • Personal needs, priorities, motivations, and behavior • How do we promote adherence to drug in non-therapeutic condition? • Products: • Unknown efficacy and incomplete safety profile • Frequency and timing of drug/product delivery • Do we have options available? • Provider: • Are providers empowered to educate their patients? • Are providers working within a strengthened health care system? • Are there linkages between ARV delivery and prevention program? • Community: • Addressing stigma and discrimination • Do we have buy-in at all levels of government?

  17. Adherence: Meet the challenge • Social science research: • For understanding stigma • Learn about the social process that sustains stigma • Impact of stigma on health-related behavior. • Develop and systematically test enhanced adherence counseling interventions • Identify drivers of adherence to ARV based prevention to provide reliable explanation of variable adherence • There is a need to leverage upon existing routines and establish client-centered relationships/ environments to support promote adherence and accurate reporting [Vitamin pills…] • Development of products that do not depend on human behaviors: InjectablePrEP. • Strategies to identify target population

  18. Retention • Retention and adherence should go beyond individual boundaries • Lessons from Link ART centre [LAC] program for retention might be useful • At program level, linkages between ARV for prevention and ARV for treatment needs to be planned • Identify individual, individual’s behavioral, family, societal and environment factors that can prevent retention in prevention program.

  19. RETENTION Program (INDIA) Retention committee HCP, Social Scientist, Community Liaison

  20. CLUB Message • Commitment to remain HIV free • Live and prevent • Understand personal challenges • Believe in yourself to adhere

  21. Acknowledgements • Indian Council of Medical Research (ICMR) • AIDS 2014 • Dr. S. M. Mehendale • Prof. S. AbdoolKarim • Dr. L. Mansoor • Dr. S. Chariyalertsak • Dr. J. de Wit • Ms. M. Francois • Dr. R. Paranjape

More Related